INTRODUCTION
G M1 gangliosidosis is an autosomal recessive lysosomal storage disease (LSD) caused by deficiency of b-galactosidase (b-gal; EC 3.2.1.23), the enzyme that hydrolyzes terminal galactose residues from numerous molecules. b-Gal deficiency leads to neuronal storage of G M1 ganglioside and its asialo derivative (G A1 ), resulting in progressive neurodegeneration and death (1, 2) . Three clinical forms exist and are thought to result from differing levels of residual enzyme activity (3) . Infantile-and juvenileonset forms are fatal by ages 5 and 15 years, respectively, whereas the adult-onset phenotype varies considerably, with some patients living into the sixth decade (2) . No effective therapy exists for G M1 gangliosidosis.
Because b-gal deficiency affects the central nervous system (CNS) globally, successful treatment strategies must target widespread areas of the brain and spinal cord. Whereas the circulatory system provides global access to the CNS for select molecules, lysosomal enzymes are excluded by the blood-brain barrier (BBB), making the task of enzyme replacement challenging. Therapeutic challenges posed by the BBB may be overcome by several key characteristics of lysosomal enzymes. First, even low concentrations of enzyme may be therapeutic, with activity in adult-onset LSD patients and clinically normal carriers reported at 2 to 4% and 11% of the activity in homozygous normal individuals, respectively (4) . Also, diseased cells are able to endocytose and use normal lysosomal enzymes, so a locus of treated cells may "cross-correct" a broad sphere of untreated neighboring tissue (5, 6) . Finally, lysosomal enzymes are distributed in the CNS by multiple mechanisms such as diffusion (7), axonal transport (8) (9) (10) , and cerebrospinal fluid (CSF) flow (8, (11) (12) (13) (14) .
Recently, adeno-associated viral (AAV) vectors have achieved widespread CNS distribution of lysosomal enzymes after injection into highly interconnected brain structures such as the ventral tegmental area, striatum, thalamus, and deep cerebellar nuclei (9, (14) (15) (16) (17) . Most G M1 mice treated by AAV injection of the thalamus and deep cerebellar nuclei survived for 52 weeks (the experimental endpoint), compared to a median survival of 38 weeks in untreated animals. b-Gal activity was restored to a presumed therapeutic level (>10% wild-type mice) throughout the CNS, with normalization of substrate storage in the brain and a 50% reduction of substrate storage in the spinal cord (17) . Because the mouse brain is 1000 times smaller than that of a human infant, we tested AAV-based gene therapy in a feline model of G M1 gangliosidosis.
First described in 1971, naturally occurring feline G M1 gangliosidosis is an accurate model of the human juvenile-onset disease in terms of enzymatic deficiency (<10% normal b-gal activity), storage levels, and CNS and peripheral organ pathology (18) (19) (20) (21) . Clinical disease progression is remarkably stereotypical, with affected cats reaching a humane endpoint at 8.0 (±0.6) months. The naturally occurring feline mutation is analogous to a well-characterized human mutation that generates normal amounts of enzymatically defective b-gal protein [that is, positive for cross-reactive material (CRM + )] (22) (23) (24) (25) . The feline brain is~20 times smaller than an infant's brain and provides a good approximation of enzyme and vector distribution challenges that need to be overcome for human gene therapy. Here, G M1 cats were treated by intracranial injection of AAV vectors encoding feline b-gal. Short-and long-term assessments of therapeutic effect included clinical and magnetic resonance imaging (MRI)-based analyses accompanied by postmortem assays to evaluate normalization of biochemical defects.
nuclei with AAV vectors expressing feline b-gal from a hybrid cytomegalovirus enhancer/chicken b-actin (CBA) promoter [serotype AAV1 (n = 8) or AAVrh8 (n = 15)]. Cats were treated with either a traditional serotype already in human use (AAV1) or a new serotype that has shown promise in mouse experiments (AAVrh8). Outcomes were assessed at 16 weeks after injection (short term, n = 7) or at the humane endpoint (long term, n = 16), defined by the inability to stand on two consecutive days. Table 1 summarizes the study design.
Sixteen weeks after a single surgery lasting~90 min, b-gal activity in G M1 cats exceeded that of normal animals (homozygous for the wildtype allele) throughout the brain and spinal cord (Fig. 1, A to C) . Activity was highest at the injection sites (Fig. 1B) and decreased with distance from the thalamus and deep cerebellar nuclei, yet b-gal staining was normal or above normal in most brain regions. Specific activity measured with a synthetic fluorogenic substrate ranged from 1.1-to 4.1-fold that of normal across all coronal brain blocks for cats treated with AAVrh8 (Table 2 ). In AAV1-treated cats, b-gal brain activity ranged from 1.4-to 4.2-fold that of normal, and there was no statistical difference in b-gal concentrations when compared to the AAVrh8 cohort (P ≥ 0.22 for each block; Table 2 and fig. S1 ).
b-Gal activity in the spinal cord at 16 weeks after injection also was near or above normal, with no statistical difference between the two AAV vectors (P ≥ 0.22 for each block; Table 2 ). When measured in seven coronal blocks from the cervical, thoracic, and lumbar spinal cord, b-gal activity ranged from 1.6-to 4.8-fold that of normal in the AAVrh8 cohort and from 0.9-to 4.2-fold that of normal in the AAV1 cohort (Fig. 1C, fig. S1 , and Table 2 ). Residual b-gal activity in untreated G M1 cats ranged from 0.0-to 0.1-fold and 0.0-to 0.04-fold that of normal in the brain and spinal cord, respectively. Both vector cohorts demonstrated statistically significant increases in b-gal activity versus ‡Animal developed seizures that were well controlled by medication. The mean age of seizure onset was 20.1 ± 7.4 months. §Cat 8-1397 had normal gait at 47.9 months of age but did not recover from an anesthetic procedure and was euthanized. Cat 9-1515 was clinically normal at 29.0 months of age but did not recover properly from anesthesia for MRI and was euthanized.
untreated animals (P ≤ 0.026 for each block). Vector genomes were detected in all brain and spinal cord blocks, demonstrating widespread dissemination from the injection sites, although vector levels did not always correlate with b-gal activity (table S1) .
CSF b-gal activity was 28-fold that of normal in the AAVrh8 cohort and 42-fold that of normal in the AAV1 cohort, which was significantly higher than in untreated G M1 cats (P = 0.026 for each cohort; Table 2 ). Additionally, b-gal activity and vector genomes were present in the liver of both AAV-treated cohorts, demonstrating dissemination of enzyme and vector to peripheral tissues after intraparenchymal injection (Table  2 and table S1 ). Liver b-gal activity measured 0.38-and 0.24-fold that of normal in the AAVrh8 and AAV1 cohorts, respectively, which was significantly higher than in untreated G M1 cats (AAVrh8, P = 0.015; AAV1, P = 0.026).
Clearance of storage material
As glycosphingolipids with complex oligosaccharide side chains containing one or more sialic acid residues (26), gangliosides can be detected colorimetrically by a variety of methods. To evaluate the clearance of stored substrate by vector-generated b-gal, we performed periodic acidSchiff (PAS) staining in the CNS of G M1 cats 16 weeks after treatment. Storage levels were substantially normalized throughout most of the brain and spinal cord, but clearance was incomplete in focal areas of the temporal lobe and cervical spinal cord ( Fig. 2A) that corresponded with sites of minimal b-gal activity in Fig. 1 .
When quantitative sialic acid assays were performed on 15 samples throughout the CNS (Fig. 2, B and C) , concentrations in untreated G M1 cats were significantly higher than normal in the cerebrum (2.5-to 3.9-fold normal; P ≤ 0.015), cerebellum (1.8-to 1.9-fold normal; P ≤ 0.015), and spinal cord (1.9-to 2.5-fold normal; P ≤ 0.015). Treatment with AAV1 or AAVrh8 significantly reduced storage in all CNS samples (P ≤ 0.026), with the exception of the caudal cerebellum from AAV1-treated cats, for which samples from only two animals were available (Fig. 2 , B and C, block h; P = 0.053). Although reduced by gene therapy, storage remained above normal in 4 of 15 samples including the temporal lobe (sample d3 in Fig. 2B ), rostral and middle cerebellum (samples f and g1 in Fig. 2B ), and cervical spinal cord (sample k in Fig. 2B ). In one sample from the frontal pole of AAVrh8-treated cats, sialic acid was reduced to 0.83-fold of normal (sample a in Fig. 2B ; P = 0.033).
Normalized activity of other lysosomal enzymes
In b-gal deficiency, the activity of other lysosomal enzymes is above normal (18, 27) . For example, lysosomal b-N-acetylhexosaminidase (EC 3.2.1.52) activity was elevated up to 3.7-fold that of normal in the CNS and 2.0-fold that of normal in the liver of untreated G M1 cats (P ≤ 0.015 for each CNS block; P = 0.015 for liver; Fig. 3 ). Treatment for 16 weeks with either AAV serotype reduced hexosaminidase activity significantly in the brain (P ≤ 0.026 for each block), spinal cord (P ≤ 0.026 for each block), and liver (P ≤ 0.026), demonstrating normalization of a secondary lysosomal biomarker after gene therapy (Fig. 3 ).
Long-term clinical benefit of AAV treatment
Long-term clinical benefit in G M1 cats was assessed after treatment with AAV1 (n = 5) or AAVrh8 (n = 7) serotypes. As shown in Table 1 , animals were treated with 3 × 10 12 to 4 × 10 12 vector genomes (vg) ("full dose," n = 9) or 1.2 × 10 13 vg when AAV1 titers made this "high dose" possible (n = 3). Statistically significant increases in survival have been achieved for both the AAV1 (P = 0.0004) and AAVrh8 (P < 0.0001) cohorts (Fig. 4A) . Currently, the mean survival of treated G M1 cats is >4.7 times that of untreated cats: 39.1 (±10.1) months for the AAV1 cohort and 37.7 (±12.4) months for the AAVrh8 cohort. Eight of 12 treated cats remain alive, most with subtle or no disease signs. The oldest cats from each vector cohort remain alive and well at 52.8 (AAV1) and 50.5 (AAVrh8) months or >6.3 times the life span of untreated cats. Of the four cats no longer living, two had normal gait at 29.0 months (9-1515) and 47.9 months (8-1397) but were euthanized because of abnormal recovery from anesthesia.
Disease onset in treated cats was delayed versus untreated G M1 controls, whose stereotypical disease progression began at 4.1 (±0.6) months of age with fine tremors of the head and tail. Clinical symptoms in untreated animals progressed to generalized muscle weakness, widebased stance, ataxia, carpal hyperextension (in 80% of cats), instability with occasional falling, loss of ambulation, and, finally, the inability to stand, which defined the humane endpoint at 8.0 (±0.6) months. Of 12 treated G M1 cats, disease onset is yet to be determined in four animals *n = 4; b-gal-specific activity was significantly higher than untreated G M1 cats (n = 4) in a to h and i to o (P ≤ 0.015 for each block), CSF (P = 0.026, n = 3, no sample available for 8-1526), and liver (P = 0.015). †n = 3; b-gal-specific activity was significantly higher than untreated G M1 cats (n = 4) in a to h and i to o (P ≤ 0.026 for each block), CSF (P = 0.026), and liver (P = 0.026). ‡n = 4; b-gal-specific activity was significantly higher than untreated G M1 cats (n = 4) in a to e, g, and h (P ≤ 0.021 for each block), CSF (P = 0.015), and liver (P = 0.015), but not in f (P = 0.15) or i to o (P ≥ 0.20 for each block). §n = 3; b-gal-specific activity was significantly higher than untreated G M1 cats (n = 4) in a to h, j to l, and n to o (P ≤ 0.025 for each block), as well in CSF (P = 0.025), but not in blocks i and m (P = 0.061), or liver (P = 0.054).
¶Not enough subjects currently available for statistical analysis. ||b-Gal activity was not significantly different between AAVrh8 (n = 4) and AAV1 (n = 3) cohorts at the 16-week time point (a to h and i to o, P ≥ 0.22 for each block; CSF, P = 0.19; liver, P = 0.43).
ranging from 34.6 to 44.9 months of age. Also, three cats whose disease onset occurred at 10.2, 36.6, and 37.0 months currently have only mild disease at 44.8, 50.5, and 52.8 months, respectively , and 9-1356).
Quality of life for treated G M1 cats has improved markedly, as measured by a clinical rating scale that reflects an animal's departure from normal function (Fig. 4, B and C) . Clinical rating scores decrease from 10 (normal function) to 1 (lateral recumbency) as animals become more debilitated by gait defects and balance disturbances/instability. Currently, minimal disease progression has been documented for five of seven animals in the AAVrh8 cohort (Fig. 4 , B and C) and four of five animals in the AAV1 cohort ( fig. S2 ), whose composite clinical rating scores at 40 months of age were 9.5 (±0.6) and 9.7 (±0.6), respectively. Whereas untreated G M1 cats have severe dysequilibrium and gait defects by 7 months of age (video S1), most treated G M1 cats remain overtly normal (video S2; 8-1485 at 34.7 months) or have only subtle gait abnormalities (video S3; 8-1435 at 39.0 months). No difference in therapeutic benefit is discernible between the AAV1 and AAVrh8 cohorts.
In 3 of 12 AAV-treated cats, therapeutic response was clearly positive but less marked. One cat that was symptomatic at the time of surgery (8-1626) has moderately progressive disease at 29.4 months of age, although current symptom acquisition has been delayed about threefold. Two animals had disease onset at 6.1 (8-1378) and 4.6 (9-1545) months of age, ultimately reaching humane endpoint at 17.5 and 25.3 months, respectively. Conclusions regarding why 3 of 12 treated animals responded less robustly than others await tissue analysis from more cats in the long-term cohort. However, diminished enzyme activity is a reasonable hypothesis because both cats that reached the humane endpoint (8-1378 and 9-1545) had low b-gal concentrations in the spinal cord (≤0.4-fold normal and ≤0.14-fold that of samples from the 16-week time point). In contrast, two cats that had normal gait at 29.0 and 47.9 months of age (9-1515 and 8-1397, respectively) had abovenormal b-gal activity in the spinal cord that was comparable to the 16-week cohort ( fig. S3 ). b-Gal activity in CSF was above normal (2.5-to 63.1-fold) in all cats from the long-term cohort, perhaps explaining why there was no correlation between CSF activity and clinical outcome/life span ( fig. S3) .
Half of all treated cats in the long-term cohort (6 of 12) experienced seizure activity, well controlled by medication, with a mean onset of 20.1 (±7.4) months (Table 1) . Common symptoms included blank stares, salivation, and facial twitches, but progression to undirected running and tonic-clonic seizures did occur in some animals. In at least three of six animals, seizures were demonstrably inducible by sounds such as running water. No seizures occurred in G M1 cats treated for only 16 weeks (n = 7). Seizures are a known feature of late-stage feline G M1 gangliosidosis (19, 21) , although no untreated G M1 cats in the current study had seizures because they occur well beyond the humane endpoint used. 1A ; half of each block was used). (C) Sialic acid levels were measured in untreated G M1 cats (n = 4) and in AAVrh8-treated (n = 4) or AAV1-treated (n = 3) G M1 cats for comparison to normal healthy cats (n = 4). *All samples from untreated G M1 cats were significantly higher than normal (P ≤ 0.015 for each block). **All samples from treated G M1 cats were significantly lower than untreated G M1 cats (P ≤ 0.026 for each block) except AAV1 block h, because only two samples were available (P = 0.053).
▵
, samples from treated G M1 cats that were significantly higher than normal (P ≤ 0.035); ▾ , a sample from treated G M1 cats that was significantly lower than normal (P = 0.033). The Wilcoxon signed-rank test was used for statistical comparisons. ▵ , a sample from treated cats that was significantly higher than normal (P = 0.026); ▾ , samples from treated cats that were significantly lower than normal (P ≤ 0.030). The Wilcoxon signed-rank test was used for statistical comparisons.
Normalization of MRI brain architecture On T2-weighted MRI, cortical white matter is hypointense to (that is, darker than) gray matter in normal cats but is hyperintense to (that is, lighter than) gray matter in untreated G M1 cats with moderate to severe disease. Also, the deep cerebellar nuclei area is hypointense to cerebellar gray matter in normal cats but becomes isointense with disease progression in untreated G M1 cats. Therefore, MRI provides an easily discernible, noninvasive biomarker of disease progression (Fig. 5) . In AAV-treated G M1 cats, hypointensity of white matter to gray matter is substantially normalized in the cortex to at least 32 months of age (cat 8-1364) or more than five times longer than in untreated cats. Additionally, hypointensity of the deep cerebellar nuclei area to surrounding gray matter is largely preserved after AAV treatment. Overall brain architecture of treated G M1 cats is normal, although slight widening of sulci is appreciated in some animals.
To date, the only abnormality associated with AAV treatment is an irregularly shaped locus of T2 hyperintensity in the thalamus of 5 of 11 cats evaluated (Fig. 5) . In previous studies of gene therapy in feline G M2 gangliosidosis (Sandhoff disease), similar hyperintense loci were thought to be associated with eosinophilic, botryoid neurons in hematoxylin and eosin sections from the dorsal thalamic nuclei (28) . In treated G M1 cats in the current study, fine eosinophilic granules were found in scattered cortical and hippocampal neurons dorsal to the injection site ( fig. S4 ), but not in thalamic regions corresponding to T2 hyperintensities. The underlying cause of hyperintense thalamic loci remains to be defined. Detected in AAV-treated cats by 6 months of age, T2 hyperintensities were not present in untreated cats at any age, including the humane endpoint of~8 months. No histological or MRI anomalies were found in three normal cats injected with saline and followed for >18 months.
Dose response
When G M1 cats were treated with 1 / 10 of the full AAVrh8 dose, mean survival was 17.1 (±3.6) months, significantly lower than the full-dose cohort (P = 0.0046, Fig. 4A ). Of four cats treated with the 1 / 10 dose, two reached the humane endpoint at 14.2 and 19.1 months of age, one was euthanized at 13.9 months because of chronic weight loss and lethargy, and one was euthanized at 21.2 months because of dysphagia, also reported in juvenile-onset G M1 patients (29) . Nevertheless, the mean survival of the 10th-dose cohort was 2.1 times greater than that of the untreated G M1 cats (P = 0.0012). b-Gal activity and vector copies for the 1 / 10 dose cohort are detailed in Table 2 and table S1 . Liver b-gal activity of only 0.17-fold that of normal was sufficient to fully normalize hexosaminidase activity (P = 0.015 versus untreated G M1 cats; fig. S5 ).
Restoration of breeding function
In >40 years of study, no female G M1 cat has become pregnant and no G M1 male has been fertile. After AAV injection, 2 treated males bred 2 treated females and 4 untreated carrier females, producing a total of 9 litters (27 kittens). Treated G M1 cats bred successfully from 9.8 to at least 28.6 months of age. Fertility onset for carrier or normal colony cats is~7 months. G M1 × G M1 matings produced litters composed entirely of G M1 kittens, which had stereotypical disease progression and life span. In agreement with previous reports (30, 31), vector was detected only transiently in gonads, and no evidence of germline gene transmission was found in treated cats or their offspring (table S2).
DISCUSSION
As a group, LSD prevalence is~1 in 7700 live births (32) , similar to that of cystic fibrosis or hemophilia. Like most lysosomal diseases, 
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Full-dose AAVrh8-treated cats were scored on a scale based on disease progression in untreated G M1 cats (No Tx). A composite of five cats that responded robustly to treatment is shown (+AAV composite), whereas two cats that responded less favorably are depicted separately (8-1626 and 8-1378). Solid lines signify living cats; dashed lines represent deceased cats. Open symbols denote whole-body tremors, which occurred in all untreated cats but only one treated animal. (C) Age of symptom onset is shown for untreated G M1 cats (mean ± SD, n = 12). The scale is based on gait defects, which ultimately defined the humane endpoint, with initial deficits appearing at 4.9 months. However, disease onset begins at 4.1 months with fine head and tail tremors that progress to whole-body tremors at 6.2 months. For clarity, only whole-body tremors are depicted in (B). G M1 gangliosidosis is neurodegenerative and fatal, with only palliative measures currently available to patients. Promising results have been achieved with intracranial AAV injections in rodent models of gangliosidosis. Treated G M2 mice demonstrate near normalization of life span, representing a more than fivefold survival increase versus untreated G M2 mice (14) . Also encouraging are data from large animal models of neurodegenerative lysosomal diseases. In dogs with mucopolysaccharidosis I or IIIb, intracranial gene therapy with AAV vectors improved storage and histological lesions throughout most of the brain, although no clinical or survival benefit was demonstrated (33, 34) . Cats with a-mannosidosis treated by intracranial injections of an AAV1 vector through 14 burr holes had only mild neurological disease at the untreated humane endpoint of 18 weeks, with restoration of a-mannosidase activity to~4% normal in the brain. Because of the study design, improved survival benefit was not achieved, although one of two treated cats followed long term had only mild disease when euthanized at 56 weeks of age (35) .
The current report documents above-normal b-gal activity throughout the G M1 cat brain and spinal cord after intracranial injections of AAV vectors carrying the therapeutic gene through only four burr holes in a surgery lasting~90 min. The successful translation of a treatment approach from G M1 mice to G M1 cats, with a~70-fold scaleup of brain size, suggests that this approach may be beneficial in human patients. Although the human infant brain is~20 times larger than the cat brain, the thalamus and deep cerebellar nuclei also are proportionally larger, allowing an equivalent AAV dose per kilogram of brain weight. In 12 treated animals followed long term, mean life span was extended >4.7-fold and continues to increase because most of the treated cats are disease-free or have only subtle symptoms at present. Quality of life improved profoundly, with only 2 of 12 treated animals having progressed to the most debilitating symptoms such as dysequilibrium and severe ataxia. Clinical outcomes were similar for the two vector serotypes tested: AAV1, currently in human clinical trials (36) (37) (38) (39) or approved for human use (40, 41) , and AAVrh8, a new serotype (42) that showed promise in a related feline model (28) .
Little toxicity was apparent from the vector. The eosinophilic granules in brain neurons of treated G M1 animals may represent a less extreme version of the large, botryoid hypereosinophilic inclusions previously reported in Sandhoff and normal cats treated with AAVrh8 vectors that overexpressed feline hexosaminidase, often at >50 times normal (28) . In our treated G M1 cats, typical b-gal expression is less than or equal to fourfold normal, so it is possible that fine eosinophilic granules represent inclusions with mildly overexpressed b-gal. Additionally, there was limited toxicity from the injection procedure. A thalamic hemorrhage documented by MRI in one animal (8-1435) caused ataxia, head tilt, and cortical blindness that resolved after 1 week of treatment with mannitol and steroids. Now >44 months of age, 8-1435 (video S3) has only slight hindlimb gait deficits and is the first fertile male in the 40-year history of the research colony.
Although about half of AAV-treated G M1 cats had hyperintense thalamic loci on T2-weighted images, no histopathological or clinical correlates were identified. In related ongoing studies, similar loci were found in the thalamus of four of six normal cats treated with AAVrh8 vectors expressing feline hexosaminidase, none of which had seizures in >18 months of follow-up. Because no seizure activity was observed in three of the five treated G M1 cats with T2 anomalies, a causal relationship between hyperintense thalamic loci and seizures is unlikely. Known to occur in late-stage G M1 disease in both humans (29, 43, 44) and cats (19, 21) , seizures in treated animals may result from progressive disease in the temporal lobe, one of the few brain regions with incomplete restoration of b-gal activity (Fig. 1B) and only partial normalization of storage (Fig. 2, A and C) . Seizures in treated G M1 cats often resemble temporal lobe epilepsy, with short duration, initial motionless stare, impaired awareness, involuntary motor behaviors, and salivation (45) (46) (47) . Improved treatment and abrogation of seizure activity may be achieved by adding injection sites that target areas of suboptimal therapeutic response.
Above-normal b-gal activity in the spinal cord after injection of the brain parenchyma was among the surprising findings of this study, even with injection targets (thalamus and deep cerebellar nuclei) (16, 17) chosen for a high degree of interconnectivity with other CNS structures. b-Gal activity and vector genomes were detected throughout the spinal cord, up to 14 cm from the deep cerebellar nuclei injection site at the time of surgery. We hypothesize that a portion of vector transport to the spinal cord occurred through CSF, known to be an effective medium for AAV transfection of the CNS (12, 13). For our thalamic injections, the needle transects the lateral ventricle, which may provide a path of least resistance for vector backflow through the needle tract. Similarly for cerebellar injections, vector may travel into the subarachnoid space dorsal to the cerebellum. Varying degrees of vector leakage into the CSF because of slight differences in needle placement or anatomy may explain the reduced b-gal activity in the spinal cord of cats that responded less robustly to treatment.
Vector likely gained access to peripheral organs via blood vessels disrupted during the injection procedure and via CSF, which ultimately is reabsorbed into the circulatory system. To date, there have been no apparent peripheral disease symptoms in AAV-treated G M1 animals. It is likely that residual b-gal activity (~5% normal) in G M1 cats delays development of clinical peripheral disease, but the increased b-gal activity in peripheral tissues of AAV-treated G M1 cats also may contribute to therapeutic success. Normalized liver activity of lysosomal hexosaminidase in all AAV-treated groups indicates that even partial restoration of liver b-gal activity is beneficial ( fig. S5 ).
Although it was not possible to blind investigators to the treatment status of cats in the present study, clinical rating scores were assigned independently by two investigators to attempt to limit bias. Survival and MRI data provided objective clinical measures, and biochemical analyses from the deceased long-term cats supported their clinical scores. The promising therapeutic results in this study after intraparenchymal injections through only four needle tracts, with little evidence of toxicity, support the initiation of AAV-based clinical trials for G M1 gangliosidosis in human patients. Although deep cerebellar nuclei injection was effective in restoring enzyme activity to the cerebellum, a similar strategy in human patients must weigh the benefit of direct cerebellar treatment versus the risk of hemorrhage in the posterior fossa. Safety studies in nonhuman primates will assess potential vector and procedural toxicity in human patients. Should the risk of deep cerebellar nuclei injection be considered too great, CSF-mediated approaches to treating the cerebellum may be incorporated, such as those deemed successful in mice and dogs (11, 13) . When predicting outcomes in human patients, it must be considered that G M1 cats in this study were treated presymptomatically, whereas most human patients are diagnosed after disease onset, so gene therapy may be less efficacious when administered later in the disease course. Nevertheless, as evidence for the benefits of AAV gene therapy continues to build in animal models, addition of future clinical trials to those already under way for human LSDs (48, 49) will determine whether this therapeutic potential is realized for G M1 gangliosidosis and for other LSDs.
MATERIALS AND METHODS
Study design objective and subjects The study objective was to evaluate intracranial AAV-mediated gene therapy in a feline model of G M1 gangliosidosis. The feline G M1 breeding colony is maintained at Auburn University, whose Institutional Animal Care and Use Committee (IACUC) approved the research described herein.
Experimental design
Treatment groups for this controlled laboratory experiment are detailed in Table 1 . G M1 cats were treated at 1.3 to 3.0 months of age. The precise age of treatment was dependent on logistical considerations, but all cats were treated at least 1 month before the average age of clinical disease onset at 4.1 ± 0.6 months. Animals were treated in the thalamus and deep cerebellar nuclei with one of three vector doses: "high," 1.2 × 10 13 vg; "full," 3 × 10 12 to 4 × 10 12 vg; or " 1 / 10 ," 3 × 10 11 vg. One of two primary endpoints was used: (i) 16 weeks after treatment (short term), for biochemical and tissue-based measures of therapeutic effect, or (ii) humane endpoint, for evaluation of long-term clinical benefit. The humane endpoint was defined by an animal's inability to stand for two consecutive days. Age-matched normal untreated controls (homozygous for the wild-type allele) were included for the short-term (n = 4) and long-term (n = 3) time points. G M1 untreated controls also were included for the short-term (6.0 to 7.3 months old, n = 4) and long-term cohorts (humane endpoint, n = 12).
Group sample sizes were based on IACUC guidelines to use the minimum number of animals necessary to derive statistical significance, which was estimated to be three or more animals for short-term studies and five or more animals for long-term studies, based on previous results from G M1 mice used to inform the experimental design. Larger sample sizes were necessary for long-term cohorts because of anticipated variability of subjective readouts such as clinical rating scores. G M1 cats were randomly assigned to each treatment group, and actual sample size (short term, n = 3 to 4; long term, n = 5 to 7) was determined by the number of viable kittens born during the treatment phase of the study.
General anesthesia was induced with ketamine (10 mg/kg) and dexmedetomidine (0.04 mg/kg) through an intravenous catheter and maintained with isoflurane (0.5 to 1.5%) in oxygen delivered through an endotracheal tube. Cats were positioned sternally for intracranial injection with a Horsley-Clark stereotaxic apparatus (David Kopf Instruments) and injected bilaterally in the thalamus and deep cerebellar nuclei with AAV1-CBA-b-gal-WPRE or AAVrh8-CBA-b-gal-WPRE (see "AAV vector design and preparation"). Craniotomy sites were made with a 20-gauge needle at the following distances (in centimeters) from bony landmarks on the skull: thalamus (relative to bregma), anteriorposterior (AP) −0.7, mediolateral (ML) ±0.4, dorsoventral (DV) −1.6 (from meninges); deep cerebellar nuclei (relative to bregma), AP 0.0, ML ±0.4, DV −1.25 (from meninges). Vector was delivered with a Hamilton syringe (Harvard Apparatus) with a noncoring needle (22 to 25 gauge). A total of 70 ml was injected into each thalamus in 10-to 20-ml boluses, and a total of 24 ml was injected into each deep cerebellar nuclei in a 10-and 14-ml bolus. Injection rate was 2 ml/min, and the needle was raised 0.15 cm between boluses.
Cats were assigned a clinical rating score from the scale in Fig. 4C with two separate, independent readouts: (i) neurological exams performed by a veterinarian at 2-to 4-week intervals and (ii) video footage, which was retrospectively analyzed by a second, independent investigator. With the personnel available, it was not possible for evaluators to be completely blinded to treatment status, although their observations were performed independently. The supplementary material contains video footage of three cats.
For biochemical analysis, brains were divided into coronal blocks of 0.6 cm from the frontal pole through the cerebellum (Fig. 1A) . Coronal blocks from the right hemisphere were frozen in optimum cutting temperature (OCT) medium and used for the following analyses: b-gal distribution by histochemical staining, b-gal-specific activity by 4-methylumbelliferone (4MU) enzyme assays (performed in duplicate for each block), AAV vector distribution by SYBR Green qPCR (quantitative polymerase chain reaction) (performed in triplicate for each block), and ganglioside storage by PAS staining. Coronal blocks from the left hemisphere were halved to 0.3 cm and fixed in 10% formalin or stored at −80°C for analysis of sialic acid levels with a resorcinol-based assay (performed in duplicate). Mean values were reported for all quantitative assays.
AAV vector design and preparation
The feline b-gal complementary DNA (cDNA) sequence was assigned GenBank accession number AF006749. AAV vectors were produced as previously described by triple transfection of 293T cells with vector plasmid [derived from the plasmid pAAV-CBA-EGFP-W by replacing enhanced green fluorescent protein (EGFP) with the cDNA for feline b-gal] (22), a mini adenovirus helper plasmid pFD6, and AAVrh8 helper plasmid pAR8 or AAV1 helper plasmid pXR1 (50) . The inverted terminal repeats in the vectors are derived from AAV2. Transgene expression is controlled by a hybrid CMV enhancer/CBA promoter. All vectors carry the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE).
Assays of lysosomal enzyme activity
For CNS tissue extraction, several frozen sections (50 mm) were cut from each coronal block (Fig. 1A) , and for liver extraction, a sample was taken from tissue stored at −80°C. Tissue was homogenized manually in 50 mM citrate phosphate buffer (pH 4.4) (50 mM citric acid, 50 mM Na 2 HPO 4 , 10 mM NaCl) containing 0.1% Triton X-100 and 0.05% bovine serum albumin, followed by two freeze-thaw cycles and centrifugation at 15,700g for 5 min at 4°C. CSF samples were analyzed directly from −80°C. The activity of b-gal and total hexosaminidase were measured with synthetic fluorogenic substrates as previously described (51), but for b-gal, we measured 10 ml of sample for brain and 30 ml for spinal cord. Specific activity was expressed as nmol 4MU/mg per hour after normalization to protein concentration by the Lowry method.
Histochemical staining of b-gal activity or storage product For analysis of b-gal activity, frozen sections at 40 mm were thawed and fixed in 0.5% glutaraldehyde in citrate phosphate buffer ( 6 , 20 mM K 3 Fe(CN) 6 , 2 mM MgCl 2 , 0.02% Igepal, 0.01% deoxycholic acid, and X-gal (2 mg/ml). The next day, sections were washed, dehydrated, and mounted.
Ganglioside storage material was assessed qualitatively with PAS staining, which detects the oligosaccharide side chain. Frozen sections (20 mm) were washed in phosphate-buffered saline (PBS), fixed for 7 min with 3.7% paraformaldehyde in 95% ethanol/5% double distilled water (ddH 2 O) (pH 7.4), washed again with PBS, incubated for 3 min in 0.5% periodic acid, washed in ddH 2 O, and incubated in Schiff reagent for 45 s (brain) or 60 s (spinal cord).
Lipid extraction and sialic acid quantification Punch biopsies of 8-mm diameter were taken from representative areas of the brain and spinal cord (Fig. 2B) and lyophilized overnight. The next day, 10 to 25 mg of dry weight sample was rehydrated in 0.5 ml of water, and total lipids were extracted in 5 ml of chloroform/methanol (1:1 by volume). Samples were stirred at room temperature for at least 4.5 hours and centrifuged at 850g for 20 min. Supernatant was collected, and the pellet was extracted again in 2 ml of chloroform/methanol for 15 min before another centrifugation. Supernatants for each sample were combined to measure sialic acid by the method of Svennerholm (52) with modification from Miettinen and Takki-Luukkainen (53) . A 0.25-ml aliquot was evaporated, redissolved in 0.5 ml of H 2 O, dissolved in 0.5 ml of resorcinol reagent (5 ml of distilled H 2 O, 40 ml of HCl, 0.125 ml of 0.1 M copper sulfate, 5 ml of 2% resorcinol stock in distilled H 2 O), and boiled for 15 min. After cooling for 10 min, 1 ml of butyl acetate/butanol solution (85:15, v/v) was added, and each sample was mixed vigorously. The upper phase was removed and read at 580 nm with a Shimadzu UV 160U spectrophotometer. Sialic acid concentration was expressed as nmol/mg. qPCR for vector genomes Vector was measured by qPCR with SYBR Green-based reactions (Applied Biosystems) with primers specific for WPRE in the vector (forward, 5′-AGTTGTGGCCCGTTGTCA-3′; reverse, 5′-GAGGGGGAAAGC-GAAAGT-3′). Samples were incubated for 2 min at 50°C, 10 min at 95°C, and then amplified for 40 cycles of 95°C for 30 s, 62°C for 30 s, and 72°C for 45 s. Genomic DNA samples (10 to 20 ng for spinal cord, 50 ng for brain, 25 ng for liver, and 100 to 250 ng for gonad) were measured in triplicate on a Bio-Rad CFX96 Real-Time System and compared to a standard curve generated from a plasmid containing WPRE (1 × 10 8 to 1 × 10 0 copies). The assay limit of detection above background was 20 AAV copies per reaction. Background amplification was determined on DNA from untreated normal and untreated G M1 cats.
Magnetic resonance imaging
Data were acquired on a 3-T MAGNETOM Verio scanner (Siemens Healthcare) with an eight-channel phased array wrist coil (Invivo Corp.). Whole-brain anatomical images were acquired with 3D MP RAGE (three-dimensional magnetization-prepared rapid gradient echo) with 0.4-mm isotropic resolution and repetition time (TR)/echo time (TE) of 1900/3.3 ms, followed by whole-brain multislice 2D axial T2 TSE (turbo-spin echo) images with TR/TE of 4630/107 ms, turbo factor of 9, and a resolution of 0.3 × 0.3 × 1 mm 3 . MRI data were analyzed with eFilm 3.2 software (Merge Healthcare).
Statistical analysis
Data are expressed as means ± SD throughout the text and figures. Statistics were performed with SAS 9.2 software, and P ≤ 0.05 was considered significant for all comparisons. The Wilcoxon signed-rank test was used for pairwise comparisons of lysosomal enzyme activity, vector distribution, and sialic acid levels. One-sided testing is reported to determine directional significance (that is, significantly higher or lower), which would not be realized using two-sided testing because of low animal numbers when using a feline model. The log-rank test was used for survival comparisons between groups. No data were excluded from analysis, and because outliers are hard to determine with small sample sizes, no data points in the study were defined as outliers.
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